Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer

Cellular and Molecular Life Sciences

Volumn 60, Issue 6, 2003, Pages 1180-1199

  Friess, H ^a   Ding, J ^b   Kleeff, J ^a   Fenkell, L ^a   Rosinski, J A ^b   Guweidhi, A ^a   Reidhaar Olson, J F ^b   Korc, M ^c   Hammer, J ^b   Buchler M W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic pancreatitis; DNA array; Gene transcription; Pancreatic cancer; TGF

Indexed keywords

GENE PRODUCT;

ADULT; ARTICLE; CANCER GROWTH; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGNOSIS; UNINDEXED SEQUENCE;

EID: 0038047893     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3036-5     Document Type: Article

References (137)

1. Greenlee R. T., Murray T., Bolden S. and Wingo P. A. (2000) Cancer statistics, 2000. CA Cancer J. Clin. 50: 7-33
2. Warshaw A. L. and Fernandez-del Castillo C. (1992) Pancreatic carcinoma. N. Engl. J. Med. 326: 455-465
3. Gudjonsson B. (1987) Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284-2303
4. Gudjonsson B. (1996) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the west Midlands: an epidemiological study. Br. J. Surg. 83: 874
5. Abrams R. A. (2001) Adjuvant therapy for pancreatic adenocarcinoma. J. Gastrointest. Surg. 5: 6-7
6. Permert J., Hafstrom L., Nygren P. and Glimelius B. (2001) A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol. 40: 361-370
7. Sohn T. A., Yeo C. J., Cameron J. L., Koniaris L., Kaushal S., Abrams R. A. et al. (2000) Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4: 567-579
8. Hanahan D. and Weinberg R. A. (2000) The hallmarks of cancer. Cell 100: 57-70
9. Friess H., Lu Z., Graber H. U., Zimmermann A., Adler G., Korc M. et al. (1998) bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421
10. Longnecker D. S. and Terhune P. G. (1998) What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas 17: 323-324
11. Friess H., Yamanaka Y., Buchler M., Berger H. G., Kobrin M. S., Baldwin R. L. et al. (1993) Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res. 53: 2704-2707
12. Wagner M., Kleeff J., Friess H., Buchler M. W. and Korc M. (1999) Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19: 370-376
13. Dunne M. J., Kane C., Shepherd R. M., Sanchez J. A., James R. F., Johnson P. R. et al. (1997) Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N. Engl. J. Med. 336: 703-706
14. Baldwin R. L., Friess H., Yokoyama M., Lopez M. E., Kobrin M. S., Buchler M. W. et al. (1996) Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int. J. Cancer 67: 283-288
15. Hahn S. A., Schutte M., Hoque A. T., Moskaluk C. A., Costa L. T. da, Rozenblum E. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353
16. Schwarte-Waldhoff I., Volpert O. V., Bouck N. P., Sipos B., Hahn S. A., Klein-Scory S. et al. (2000) Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. USA 97: 9624-9629
17. Su G. H., Bansal R., Murphy K. M., Montgomery E., Yeo C. J., Hruban R. H. et al. (2001) ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98: 3254-3257
18. Wagner M., Kleeff J., Lopez M. E., Bockman I., Massaque J. and Korc M. (1998) Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int. J. Cancer 78: 255-260
19. Goggins M., Shekher M., Turnacioglu K., Yeo C. J., Hruban R. H. and Kern S. E. (1998) Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58: 5329-5332
20. Kleeff J., Ishiwata T., Maruyama H., Friess H., Truong P., Buchler M. W. et al. (1999) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363-5372
21. Naumann M., Savitskaia N., Eilert C., Schramm A., Kalthoff H. and Schmiegel W. (1996) Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110: 1215-1224
22. Dong M., Nio Y., Tamura K., Song M. M., Guo K. J., Guo R. X. et al. (2000) Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol. Biomarkers Prev. 9: 279-284
23. Friess H., Buchler M. W., Mueller C. and Malfertheiner P. (1998) Immunopathogenesis of chronic pancreatitis. Gastroenterology 115: 1018-1022
24. Graber H. U., Friess H., Zimmermann A., Korc M., Adler G., Schmid R. et al. (1999) Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J. Gastrointest. Surg. 3: 74-81
25. Gansauge S., Gansauge F., Yang Y., Muller J., Seufferlein T., Ramadani M. et al. (1998) Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res. 58: 2703-2706
26. Raitano A. B., Scuderi P. and Korc M. (1990) Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 5: 267-277
27. Ungefroren H., Voss M., Jansen M., Roeder C., Henne-Bruns D., Kremer B. et al. (1998) Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 58: 1741-1749
28. Ozawa F., Friess H., Kleeff J., Xu Z. W., Zimmermann A., Sheikh M. S. et al. (2001) Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 163: 71-81
29. Buchler P., Conejo-Garcia J. R., Lehmann G., Muller M., Emrich T., Reber H. A. et al. (2001) Real-time quantitative PCR of telomerase mRNA is useful for the differentiation of benign and malignant pancreatic disorders. Pancreas 22: 331-340
30. Hiyama E., Kodama T., Shinbara K., Iwao T., Itoh M., Hiyama K. et al. (1997) Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 57: 326-331
31. Tsutsumi M., Tsujiuchi T., Ishikawa O., Majima T., Yoshimoto M., Sasaki Y. et al. (1997) Increased telomerase activities in human pancreatic duct adenocarcinomas. Jpn. J. Cancer Res. 88: 971-976
32. Itakura J., Ishiwata T., Friess H., Fujii H., Matsumoto Y., Buchler M. W. et al. (1997) Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3: 1309-1316
33. Itakura J., Ishiwata T., Shen B., Kornmann M. and Korc M. (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85: 27-34
34. Seo Y., Baba H., Fukuda T., Takashima M. and Sugimachi K. (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88: 2239-2245
35. Bramhall S. R., Neoptolemos J. P., Stamp G. W. and Lemoine N. R. (1997) Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J. Pathol. 182: 347-355
36. Ellenrieder V., Alber B., Lacher U., Hendler S. F., Menke A., Boeck W. et al. (2000) Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int. J. Cancer 85: 14-20
37. Cantero D., Friess H., Deflorin J., Zimmermann A., Brundler M. A., Riesle E. et al. (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer 75: 388-395
38. Koliopanos A., Friess H., Kleeff J., Shi X., Liao Q., Pecker I. et al. (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 61: 4655-4659
39. Vogelmann R., Kreuser E. D., Adler G. and Lutz M. P. (1999) Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells. Int. J. Cancer 80: 791-795
40. Furuyama H., Arii S., Mori A. and Imamura M. (2000) Role of E-cadherin in peritoneal dissemination of the pancreatic cancer cell line, panc-1, through regulation of cell to cell contact. Cancer Lett. 157: 201-209
41. Ellenrieder V., Adler G. and Gress T. M. (1999) Invasion and metastasis in pancreatic cancer. Ann. Oncol. 10: 46-50
42. Wodicka L., Dong H., Mittmann M., Ho M. H. and Lockhart D. J. (1997) Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15: 1359-1367
43. Eisen M. B., Spellman P. T., Brown P. O. and Botstein D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95: 14863-14868
44. Friess H., Yamanaka Y., Buchler M., Ebert M., Beger H. G., Gold L. I. et al. (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856
45. Kleeff J., Friess H., Simon P., Susmallian S., Buchler P., Zimmermann A. et al. (1999) Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Dig. Dis. Sci. 44: 1793-1802
46. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N. et al. (1996) TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272: 1179-1182
47. Kleeff J., Friess H., Berberat P. O., Martignoni M. E., Z'-Graggen K. and Buchler M. W. (2000) Pancreatic cancer - new aspects of molecular biology research. Swiss Surg. 6: 231-234
48. Friess H., Kleeff J., Korc M. and Buchler M. W. (1999) Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. 16: 281-290
49. Wallrapp C., Muller-Pillasch F., Micha A., Wenger C., Geng M., Solinas-Toldo S. et al. (1999) Novel technology for detection of genomic and transcriptional alterations in pancreatic cancer. Ann. Oncol. 10 (suppl) 4: 64-68
50. Iacobuzio-Donahue C. A., Maitra A., Shen-Ong G. L., Heek T. van, Ashfaq R., Meyer R. et al. (2002) Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160: 1239-1249
51. Korc M., Chandrasekar B., Yamanaka Y., Friess H., Buchier M. and Beger H. G. (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90: 1352-1360
52. Saitoh E., Isemura S., Sanada K. and Ohnishi K. (1991) The human cystatin gene family: cloning of three members and evolutionary relationship between cystatins and Bowman-Birk type proteinase inhibitors. Biomed. Biochim. Acta 50: 599-605
53. Lignelid H. and Jacobsson B. (1992) Cystatin C in the human pancreas and gut: an immunohistochemical study of normal and neoplastic tissues. Virchows Arch. A Pathol. Anat. Histopathol. 421: 491-495
54. Sexton P. S. and Cox J. L. (1997) Inhibition of motility and invasion of B16 melanoma by the overexpression of cystatin C. Melanoma Res. 7: 97-101
55. Pavlova A., Krupa J. C., Mort J. S., Abrahamson M. and Bjork I. (2000) Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop: demonstration by release of loop anchoring through mutation of his110. FEBS Lett. 487: 156-160
56. Morita M., Yoshiuchi N., Arakawa H. and Nishimura S. (1999) CMAP: a novel cystatin-like gene involved in liver metastasis. Cancer Res. 59: 151-158
57. Morrison B. W., Moorman J. R., Kowdley G. C., Kobayashi Y. M., Jones L. R. and Leder P. (1995) Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes. J. Biol. Chem. 270: 2176-2182
58. Sweadner K. J. and Rael E. (2000) The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics 68: 41-56
59. Soroceanu L., Manning T. J. Jr and Sontheimer H. (1999) Modulation of glioma cell migration and invasion using C1(-) and K(+) ion channel blockers. J. Neurosci. 19: 5942-5954
60. Morrison B. W. and Leder P. (1994) neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 9: 3417-3426
61. Yamanaka Y., Friess H., Kobrin M. S., Buchler M., Kunz J., Beger H. G. et al. (1993) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 24: 1127-1134
62. Imasato Y., Xuan J. W., Sakai H., Izawa J. I., Saito Y., Chin J. L. et al. (2000) PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J. Urol. 164: 1819-1824
63. Weiber H., Borch K., Sundler F. and Fernlund P. (1999) Beta-microseminoprotein in gastric carcinoids: a marker of tumour progression. Digestion 60: 440-448
64. Sakai H., Tsurusaki T., Kanda S., Koji T., Xuan J. W. and Saito Y. (1999) Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 38: 278-284
65. Cheng M., Watson P. H., Paterson J. A., Seidah N., Chretien M. and Shiu R. P. (1997) Pro-protein convertase gene expression in human breast cancer. Int. J. Cancer 71: 966-971
66. Kamiyama F., Maeda T., Yamane T., Li Y. H., Ogukubo O., Otsuka T. et al. (2001) Inhibition of vitronectin-mediated haptotaxis and haptoinvasion of MG-63 cells by domain 5 (D5(H)) of human high-molecular-weight kininogen and identification of a minimal amino acid sequence. Biochem Biophys. Res. Commun. 288: 975-980
67. Bosserhoff A. K., Echtenacher B., Hein R. and Buettner R. (2001) Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 11: 417-421
68. Errabolu R., Sanders M. A. and Salisbury J. L. (1994) Cloning of a cDNA encoding human centrin, an EF-hand protein of centrosomes and mitotic spindle poles. J. Cell Sci. 107: 9-16
69. Azuma T., Liu W. G., Vander Laan D. J., Bowcock A. M. and Taggart R. T. (1992) Human gastric cathepsin E gene: multiple transcripts result from alternative polyadenylation of the primary transcripts of a single gene locus at 1q31-q32. J. Biol. Chem. 267: 1609-1614
70. Azuma T., Hirai M., Ito S., Yamamoto K., Taggart R. T., Matsuba T. et al. (1996) Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Int. J. Cancer 67: 492-497
71. Uno K., Azuma T., Nakajima M., Yasuda K., Hayakumo T., Mukai H. et al. (2000) Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J. Gastroenterol. Hepatol. 15: 1333-1338
72. Tani T., Lumme A., Linnala A., Kivilaakso E., Kiviluoto T., Burgeson R. E. et al. (1997) Pancreatic carcinomas deposit laminin-5, preferably adhere to laminin-5, and migrate on the newly deposited basement membrane. Am. J. Pathol. 151: 1289-1302
73. Pulkkinen L., Gerecke D. R., Christiano A. M., Wagman D. W., Burgeson R. E. and Uitto J. (1995) Cloning of the beta 3 chain gene (LAMB3) of human laminin 5, a candidate gene in junctional epidermolysis bullosa. Genomics 25: 192-198
74. Robbins P. B., Lin Q., Goodnough J. B., Tian H., Chen X. and Khavari P. A. (2001) In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc. Natl. Acad. Sci. USA 98: 5193-5198
75. Ohnami S., Matsumoto N., Nakano M., Aoki K., Nagasaki K., Sugimura T. et al. (1999) Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res. 59: 5565-5571
76. Takahashi S., Hasebe T., Oda T., Sasaki S., Kinoshita T., Konishi M. et al. (2002) Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 94: 1894-1901
77. Grotzinger C., Kneifel J., Patschan D., Schnoy N., Anagnostopoulos I., Faiss S. et al. (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 49: 73-81
78. Mercurio A. M. and Rabinovitz I. (2001) Towards a mechanistic understanding of tumor invasion - lessons from the alpha6beta 4 integrin. Semin. Cancer Biol. 11: 129-141
79. Chang K. S., Wang G., Freireich E. J., Daly M., Naylor S. L., Trujillo J. M. et al. (1992) Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 79: 1802-1810
80. Kleeff J., Kusama T., Rossi D. L., Ishiwata T., Maruyama H., Friess H. et al. (1999) Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81: 650-657
81. Parsons S. L., Watson S. A., Brown P. D., Collins H. M. and Steele R. J. (1997) Matrix metalloproteinases. Br. J. Surg. 84: 160-166
82. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2: 737-744
83. Balaz P., Friess H., Kondo Y., Zhu Z., Zimmermann A. and Buchler M. W. (2002) Human macrophage metalloelastase worsens the prognosis of pancreatic cancer. Ann. Surg. 235: 519-527
84. Takeshita S., Kikuno R., Tezuka K. and Amann E. (1993) Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem. J. 294: 271-278
85. Sugiura T., Takamatsu H., Kudo A. and Amann E. (1995) Expression and characterization of murine osteoblast-specific factor 2 (OSF-2) in a baculovirus expression system. Protein Express. Purif. 6: 305-311
86. Kleeff J., Maruyama H., Ishiwata T., Sawhney H., Friess H., Buchler M. W. et al. (1999) Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 1202-1216
87. Engelkamp D., Schafer B. W., Mattei M. G., Erne P. and Heizmann C. W. (1993) Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E. Proc. Natl. Acad. Sci. USA 90: 6547-6551
88. Hough C. D., Cho K. R., Zonderman A. B., Schwartz D. R. and Morin P. J. (2001) Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61: 3869-3876
89. Wicki R., Franz C., Scholl F. A., Heizmann C. W. and Schafer B. W. (1997) Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 22: 243-254
90. Lauriola L., Michetti F., Maggiano N., Galli J., Cadoni G., Schafer B. W. et al. (2000) Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma. Int. J. Cancer 89: 345-349
91. Vercoutter-Edouart A. S., Lemoine J., Le Bourhis X., Louis H., Boilly B., Nurcombe V. et al. (2001) Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res. 61: 76-80
92. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H. and Imai K. (2000) Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res. 60: 4353-4357
93. Yaffe M. B., Rittinger K., Volinia S., Caron P. R., Aitken A., Leffers H. et al. (1997) The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91: 961-971
94. Hermeking H., Lengauer C., Polyak K., He T. C., Zhang L., Thiagalingam S. et al. (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1: 3-11
95. Hoover K. B., Liao S. Y. and Bryant P. J. (1998) Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am. J. Pathol. 153: 1767-1773
96. Kleeff J., Shi X., Bode H. P., Hoover K., Shrikhande S., Bryant P. J. et al. (2001) Altered expression and localization of the tight junction protein ZO-1 in primary and metastatic pancreatic cancer. Pancreas 23: 259-265
97. Magee J. A., Araki T., Patil S., Ehrig T., True L., Humphrey P. A. et al. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61: 5692-5696
98. Tanimoto H., Yan Y., Clarke J., Korourian S., Shigemasa K., Parmley T. H. et al. (1997) Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 57: 2884-2887
99. Torres-Rosado A., O'Shea K. S., Tsuji A., Chou S. H. and Kurachi K. (1993) Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc. Natl. Acad. Sci. USA 90: 7181-7185
100. Wallrapp C., Hahnel S., Muller-Pillasch F., Burghardt B., Iwamura T., Ruthenburger M. et al. (2000) A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 60: 2602-2606
101. Bini L., Magi B., Marzocchi B., Arcuri F., Tripodi S., Cintorino M. et al. (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18: 2832-2841
102. Tager M., Kroning H., Thiel U. and Ansorge S. (1997) Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp. Hematol. 25: 601-607
103. Stossel T. P., Condeelis J., Cooley L., Hartwig J. H., Noegel A., Schleicher M. et al. (2001) Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol. 2: 138-145
104. Stahlhut M. and Deurs B. van (2000) Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol. Biol. Cell 11: 325-337
105. Yuan Y. and Shen Z. (2001) Interaction with BRCA2 suggests a role for filamin-1 (hsFLNa) in DNA damage response. J. Biol. Chem. 276: 48318-48324
106. Marti A., Luo Z., Cunningham C., Ohta Y., Hartwig J., Stossel T. P. et al. (1997) Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor-alpha activation of SAPK in melanoma cells. J. Biol. Chem. 272: 2620-2628
107. Porter R. M., Holme T. C., Newman E. L., Hopwood D., Wilkinson J. M. and Cuschieri A. (1993) Monoclonal antibodies to cytoskeletal proteins: an immunohistochemical investigation of human colon cancer. J. Pathol. 170: 435-440
108. Kleeff J., Kornmann M., Sawhney H. and Korc M. (2000) Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int. J. Cancer 86: 399-407
109. Hayes J. D. and Pulford D. J. (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30: 445-600
110. Strange R. C., Spiteri M. A., Ramachandran S. and Fryer A. A. (2001) Glutathione-S-transferase family of enzymes. Mutat. Res. 482: 21-26
111. Ulrich A. B., Schmied B. M., Standop J., Schneider M. B., Lawson T. A., Friess H. et al. (2002) Differences in the expression of glutathione S-transferases in normal pancreas, chronic pancreatitis, secondary chronic pancreatitis, and pancreatic cancer. Pancreas 24: 291-297
112. Coles B. F., Anderson K. E., Doerge D. R., Churchwell M. I., Lang N. P. and Kadlubar F. F. (2000) Quantitative analysis of interindividual variation of glutathione S-transferase expression in human pancreas and the ambiguity of correlating genotype with phenotype. Cancer Res. 60: 573-579
113. Duell E. J., Holly E. A., Bracci P. M., Liu M., Wiencke J. K. and Kelsey K. T. (2002) A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J. Natl. Cancer Inst. 94: 297-306
114. Lowenfels A. B., Maisonneuve P., Cavallini G., Ammann R. W., Lankisch P. G., Andersen J. R. et al. (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328: 1433-1437
115. Liotta L. and Petricoin E. (2000) Molecular profiling of human cancer. Nat. Rev. Genet. 1: 48-56
116. Tapper J., Kettunen E., El-Rifai W., Seppala M., Andersson L. C. and Knuutila S. (2001) Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 128: 1-6
117. Ono K., Tanaka T., Tsunoda T., Kitahara O., Kihara C., Okamoto A. et al. (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60: 5007-5011
118. Hong T. M., Yang P. C., Peck K., Chen J. J., Yang S. C., Chen Y. C. et al. (2000) Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am. J. Respir. Cell. Mol. Biol. 23: 355-363
119. Fung L. F., Lo A. K., Yuen P. W., Liu Y., Wang X. H. and Tsao S. W. (2000) Differential gene expression in nasopharyngeal carcinoma cells. Life Sci. 67: 923-936
120. Barlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M. L. et al. (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92: 1252-1259
121. Perou C. M., Sorlie T., Eisen M. B., Rijn M. van de, Jeffrey S. S., Rees C. A. et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
122. Kitahara O., Furukawa Y., Tanaka T., Kihara C., Ono K., Yanagawa R. et al. (2001) Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res. 61: 3544-3549
123. Hernandez A., Smith F., Wang Q., Wang X. and Evers B. M. (2000) Assessment of differential gene expression patterns in human colon cancers. Ann. Surg. 232: 576-585
124. Bull J. H., Ellison G., Patel A., Muir G., Walker M., Underwood M. et al. (2001) Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br. J. Cancer 84: 1512-1519
125. Vaarala M. H., Porvari K., Kyllonen A. and Vihko P. (2000) Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab. Invest. 80: 1259-1268
126. Elek J., Park K. H. and Narayanan R. (2000) Microarray-based expression profiling in prostate tumors. In Vivo 14: 173-182
127. Villaret D. B., Wang T., Dillon D., Xu J., Sivam D., Cheever M. A. et al. (2000) Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 110: 374-381
128. Graveel C. R., Jatkoe T., Madore S. J., Holt A. L. and Farnham P. J. (2001) Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene 20: 2704-2712
129. El-Rifai W., Frierson H. F. Jr, Harper J. C., Powell S. M. and Knuutila S. (2001) Expression profiling of gastric adenocarcinoma using cDNA array. Int. J. Cancer 92: 832-838
130. Pandita A., Zielenska M., Thorner P., Bayani J., Godbout R., Greenberg M. et al. (1999) Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia 1: 262-275
131. Su Y. A., Bittner M. L., Chen Y., Tao L., Jiang Y., Zhang Y. et al. (2000) Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles. Mol. Carcinog. 28: 119-127
132. Chan W. P., Fung M. L., Nobiling R. and Leung P. S. (2000) Activation of local renin-angiotensin system by chronic hypoxia in rat pancreas. Mol. Cell. Endocrinol. 160: 107-114
133. Clark E. A., Golub T. R., Lander E. S. and Hynes R. O. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535
134. Chen K. T., Lin J. D., Chao T. C., Hsueh C., Chang C. A., Weng H. F. et al. (2001) Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11: 41-46
135. Cho Y. S., Kim M. K., Cheadle C., Neary C., Becker K. G. and Cho-Chung Y. S. (2001) Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. USA 98: 9819-9823
136. Obexer P., Certa U., Kofler R. and Helmberg A. (2001) Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis. Oncogene 20: 4324-4336
137. Kudoh K., Ramanna M., Ravatn R., Elkahloun A. G., Bittner M. L., Meltzer P. S. et al. (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60: 4161-4166